丰原药业(000153) - 2016 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2016 was CNY 426,497,365.94, representing a 7.67% increase compared to CNY 396,124,925.56 in the same period last year[8] - The net profit attributable to shareholders was CNY 6,500,659.89, showing a slight decrease of 0.29% from CNY 6,519,779.17 in the previous year[8] - The net profit after deducting non-recurring gains and losses increased by 51.96% to CNY 6,259,257.23 from CNY 4,118,914.27 year-on-year[8] - The weighted average return on net assets was 0.57%, slightly up from 0.54% in the previous year[8] - The company anticipates significant changes in net profit for the first half of 2016 compared to the same period last year[19] Cash Flow - The net cash flow from operating activities decreased by 34.04% to CNY 8,616,181.49, down from CNY 13,061,818.52 in the previous year[8] - Net cash flow from operating activities decreased by 34.04% to ¥8,616,181.49 due to increased cash payments related to operating activities[15] - Net cash flow from investing activities worsened by 47.22% to -¥49,043,405.56 mainly due to increased cash payments for subsidiaries and other business units[15] - Net cash flow from financing activities increased by 311.47% to ¥58,633,277.36 due to higher cash inflows related to financing activities[15] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,445,648,835.72, reflecting a 4.53% increase from CNY 2,339,617,000.91 at the end of the previous year[8] - The net assets attributable to shareholders decreased by 2.87% to CNY 1,137,467,691.43 from CNY 1,171,125,475.96 at the end of the previous year[8] - Accounts receivable decreased by 44.12% to ¥20,115,933.77 due to the company's discounting or endorsement of bills for payment[15] - Engineering materials increased by 178.84% to ¥5,219,959.39 primarily due to the procurement of materials for the relocation project of Wuwei Pharmaceutical[15] - Notes payable surged by 500.02% to ¥85,712,884.33 as the company increased payments via bank acceptance bills[15] - Asset impairment losses rose by 276.24% to ¥1,776,978.65 due to an increase in bad debt provisions[15] - The company repaid long-term borrowings, resulting in a 100% decrease in long-term loans to ¥0.00[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 39,657[11] - The top ten shareholders held a total of 55.93% of the company's shares, with the largest shareholder holding 11.48%[11] Non-Operating Activities - Operating income from non-operating activities decreased by 84.50% to ¥477,221.83 due to a reduction in government subsidies received compared to the previous year[15] - The company acquired 100% equity of Huainan Taifeng Pharmaceutical Co., Ltd. during the reporting period[8]